Phase three of the tests of NVX CoV2373 vaccine took place in Great Britain. The research involved more than 15,000 participants aged fgrom 18 to 84. 27 percent of these people were over 65.
The company claimed that the drug proved to be 100%-effective in tough cases.
"In a smaller trial conducted in South Africa - where volunteers were primarily exposed to another newer, more contagious variant widely circulating there and spreading around the world - the Novavax vaccine was 55% effective, based on people without HIV, but still fully prevented severe illness", reads the story.
Novavax plans to develop their vaccine on eight production playgrounds, including the Indian Institute of Serum.
Earlier, Ukraine successfully completed the negotiations on the increase of supplies of Novavax. The government managed to make a deal on the supply of another 5,000,000 doses; the general amount is supposed to make 15,000,000 doses.